Axicabtagene ciloleucel is in clinical development as treatment for adult patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). In NHL, the affected lymphocytes start to multiply in an abnormal way and begin to collect in certain parts of the body, such as the lymph nodes. Indolent, or low grade NHL tends to grow very slowly. Types of low-grade NHL include follicular and marginal zone lymphoma. Relapse means that the lymphoma has come back after going into complete remission. Lymphoma that does not go into remission with treatment is known as refractory lymphoma. Treatment options for relapsed/refractory indolent NHL after two priori treatments are limited.
Axicabtagene ciloleucel is an advanced therapy that contains the patient’s own white blood cell (T-cells) that have been modified genetically in the laboratory so that they make a protein called chimeric antigen receptor (CAR). The CAR T-cells attach to another protein on the surface of cancer cells and causing the cells to die. If licensed, axicabtagene ciloleucel will offer an additional treatment for patients with relapsed/refractory indolent NHL including follicular and marginal zone lymphoma.
Selpercatinib is in clinical development for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer and at the metastatic stage the disease has already spread from the lungs to other sites. Around 2% of these patients will have tumours that contain fusion mutations in the RET gene. Cells in these tumour produce altered RET signalling receptors that allow uncontrolled cancer growth. Currently the only treatment options that attempt to inhibit RET fusion-positive tumour activity are nonselective multikinase inhibitors.